Quadrant Capital Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Quadrant Capital Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24	Closed	-$2K	–	2889
2022 Q2	$2K	Buy	+24	New	+$1.07K	﹤0.01%	2305
2022 Q1	–	Sell	-39	Closed	-$2K	–	2771
2021 Q4	$2K	Buy	39 +37	+1,850%	+$1.65K	﹤0.01%	2214
2021 Q3	$0	Sell	2 -5	-71%	-$356	﹤0.01%	2717
2021 Q2	$1K	Buy	+7	New	+$517	﹤0.01%	2371

Quadrant Capital Group's TPTX Position: Q3 2022 in Review

Quadrant Capital Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 24 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in TPTX in Q2 2021 and held it in 4 quarters. The position peaked at $2K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Quadrant Capital Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Quadrant Capital Group sold 24 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2K.
Quadrant Capital Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Quadrant Capital Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $2K in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Quadrant Capital Group's 13F filing for Q3 2022, filed 10 Nov 2022.